CU24340B1 - Derivados de acetamidas fluoradas para el tratamiento del vih - Google Patents

Derivados de acetamidas fluoradas para el tratamiento del vih

Info

Publication number
CU24340B1
CU24340B1 CUP2015000096A CU20150096A CU24340B1 CU 24340 B1 CU24340 B1 CU 24340B1 CU P2015000096 A CUP2015000096 A CU P2015000096A CU 20150096 A CU20150096 A CU 20150096A CU 24340 B1 CU24340 B1 CU 24340B1
Authority
CU
Cuba
Prior art keywords
hiv
derivatives
acetamids
fluorated
treatment
Prior art date
Application number
CUP2015000096A
Other languages
English (en)
Other versions
CU20150096A7 (es
Inventor
Gediminas Brizgys
Eda Canales
Chien-Hung Chou
Michael Graupe
Randall L Halcomb
Yunfeng Eric Hu
Scott E Lazerwith
John O Link
Qi Liu
Yafan Lu
Roland D Saito
Scott D Schroeder
John R Somoza
Winston C Tse
Jennifer R Zhang
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50382584&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24340(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CU20150096A7 publication Critical patent/CU20150096A7/es
Publication of CU24340B1 publication Critical patent/CU24340B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

<p>En la presente solicitud se proveen derivados de acetamidas fluoradas o sales farmacéuticamente aceptables, para tratar una infección viral por Retroviridae incluyendo un infección causada por el virus de inmunodeficiencia humana (VIH).</p> <p>ESPACIO PARA FÓRMULA</p>
CUP2015000096A 2013-03-01 2014-02-28 Derivados de acetamidas fluoradas para el tratamiento del vih CU24340B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361771655P 2013-03-01 2013-03-01
US201361857636P 2013-07-23 2013-07-23
PCT/US2014/019663 WO2014134566A2 (en) 2013-03-01 2014-02-28 Therapeutic compounds

Publications (2)

Publication Number Publication Date
CU20150096A7 CU20150096A7 (es) 2016-07-29
CU24340B1 true CU24340B1 (es) 2018-05-08

Family

ID=50382584

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2015000096A CU24340B1 (es) 2013-03-01 2014-02-28 Derivados de acetamidas fluoradas para el tratamiento del vih

Country Status (37)

Country Link
US (4) US20140303164A1 (es)
EP (3) EP2961742B1 (es)
JP (5) JP6519486B2 (es)
KR (1) KR102229989B1 (es)
CN (2) CN105705500B (es)
AP (1) AP2015008717A0 (es)
AU (3) AU2014223973B2 (es)
BR (1) BR112015021027B1 (es)
CA (2) CA3007006A1 (es)
CL (1) CL2015002445A1 (es)
CR (2) CR20190504A (es)
CU (1) CU24340B1 (es)
CY (1) CY1121047T1 (es)
DK (1) DK2961742T3 (es)
EA (1) EA035127B1 (es)
ES (2) ES2887578T3 (es)
HK (3) HK1222169A1 (es)
HR (1) HRP20181679T1 (es)
HU (1) HUE039521T2 (es)
IL (1) IL240519B (es)
LT (1) LT2961742T (es)
MD (1) MD20150092A2 (es)
MX (1) MX2015011478A (es)
MY (1) MY195364A (es)
NZ (3) NZ742681A (es)
PE (2) PE20191461A1 (es)
PH (1) PH12015501881A1 (es)
PL (2) PL2961742T3 (es)
PT (2) PT2961742T (es)
RS (1) RS57718B1 (es)
SG (2) SG10201710764YA (es)
SI (2) SI2961742T1 (es)
TW (2) TWI694071B (es)
UA (1) UA120346C2 (es)
UY (1) UY35362A (es)
WO (1) WO2014134566A2 (es)
ZA (1) ZA201506098B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6205354B2 (ja) 2011-07-06 2017-09-27 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のための化合物
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
WO2014110298A1 (en) 2013-01-09 2014-07-17 Gilead Sciences, Inc. 5-membered heteroaryls and their use as antiviral agents
TWI694071B (zh) * 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2014144545A2 (en) * 2013-03-15 2014-09-18 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
PT3186239T (pt) 2014-08-29 2019-01-10 Gilead Sciences Inc Agentes antirretrovirais
US9855230B2 (en) 2014-09-09 2018-01-02 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US20160145344A1 (en) * 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
KR20230130175A (ko) 2014-12-26 2023-09-11 에모리 유니버시티 Ｎ4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도
US10526323B2 (en) 2015-01-30 2020-01-07 Vanderbilt University Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
CA2983162A1 (en) * 2015-04-23 2016-10-27 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
UY36648A (es) 2015-04-23 2016-11-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Inhibidores de la replicación del virus de inmunodeficiencia humana
US20170040479A1 (en) 2015-08-07 2017-02-09 Solaero Technologies Corp. Reliable interconnection of solar cells
US20170081324A1 (en) * 2015-09-18 2017-03-23 F. Hoffmann-La Roche Ag Triazolones derivatives and their use in the treatment, amelioration or prevention of a viral disease
US10493070B2 (en) 2016-06-30 2019-12-03 Viiv Healthcare Uk (No. 5) Limited Azadecalin derivatives as inhibitors of human immunodeficiency virus replication
JP2019519571A (ja) 2016-06-30 2019-07-11 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製のアザ置換阻害剤
EP3478703A1 (en) 2016-06-30 2019-05-08 ViiV Healthcare UK (No.5) Limited Triterpenoid inhibitors of human immunodeficiency virus replication
PE20190910A1 (es) * 2016-08-19 2019-06-26 Gilead Sciences Inc Compuestos terapeuticos utiles para el tratamiento profilactico o terapeutico de una infeccion por el virus del vih
EA036921B1 (ru) * 2017-02-10 2021-01-15 Джилид Сайэнс, Инк. Терапевтические соединения, которые можно применять для профилактического или терапевтического лечения инфекции вирусом вич
TW201906834A (zh) 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
AR112412A1 (es) * 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
AR112413A1 (es) * 2017-08-17 2019-10-23 Gilead Sciences Inc Formas sólidas de un inhibidor de la cápside del vih
AU2018378832B9 (en) 2017-12-07 2021-05-27 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
CA3175557A1 (en) * 2018-02-16 2019-08-22 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
WO2019198024A1 (en) 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
WO2020018459A1 (en) 2018-07-16 2020-01-23 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
EP3833436A1 (en) 2018-08-09 2021-06-16 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2020053811A1 (en) 2018-09-14 2020-03-19 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP7433303B2 (ja) 2018-09-20 2024-02-19 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤
WO2020084492A1 (en) 2018-10-24 2020-04-30 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US20210395262A1 (en) 2018-10-24 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
PT3870575T (pt) 2018-10-25 2023-05-12 Viiv Healthcare Uk No 5 Ltd Inibidores da replicação do vírus da imunodeficiência humana
ES2969030T3 (es) 2018-10-29 2024-05-16 Viiv Healthcare Uk No 5 Ltd Derivados de quinazolinil-indazol y su uso como inhibidores de replicación de virus de inmunodeficiencia humana
US20210379071A1 (en) 2018-11-05 2021-12-09 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2020095177A1 (en) 2018-11-05 2020-05-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
UY38559A (es) 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
JP2022531251A (ja) 2019-04-30 2022-07-06 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド ヒト免疫不全ウイルス複製阻害剤
WO2020254985A1 (en) 2019-06-19 2020-12-24 VIIV Healthcare UK (No.5) Limited Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
JP2022551256A (ja) 2019-10-01 2022-12-08 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド ヒト免疫不全ウイルスの複製阻害剤
US20220389007A1 (en) 2019-10-01 2022-12-08 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
TW202128648A (zh) 2019-10-04 2021-08-01 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑
US20220370451A1 (en) 2019-10-08 2022-11-24 VIIV HEALTHCARE UK ( No. 5) LIMITED Inhibitors of human immunodeficiency virus replication
EP4065116A1 (en) 2019-11-26 2022-10-05 Gilead Sciences, Inc. Capsid inhibitors for the prevention of hiv
WO2021107066A1 (ja) 2019-11-28 2021-06-03 塩野義製薬株式会社 インテグラーゼ阻害剤及び抗ｈｉｖ薬を組み合わせることを特徴とするｈｉｖ感染症の予防及び治療用医薬
MX2022006489A (es) * 2019-11-29 2022-07-04 Jiangsu Hengrui Medicine Co Derivado de anillo de piridina fusionado, metodo de preparacion y usos farmaceuticos del mismo.
CN115135647A (zh) * 2020-01-30 2022-09-30 先正达农作物保护股份公司 杀有害生物活性的稠合二环杂芳香族氨基化合物
KR20220151655A (ko) 2020-03-06 2022-11-15 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제
JP2023517312A (ja) 2020-03-06 2023-04-25 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド ヒト免疫不全ウイルスの複製阻害剤
AU2021237718B2 (en) 2020-03-20 2023-09-21 Gilead Sciences, Inc. Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
BR112022020933A2 (pt) 2020-04-15 2022-12-06 Viiv Healthcare Uk No 5 Ltd Inibidores de replicação do vírus da imunodeficiência humana
WO2021262990A1 (en) 2020-06-25 2021-12-30 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CN116437958A (zh) 2020-11-11 2023-07-14 吉利德科学公司 鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法
TW202313584A (zh) * 2021-05-28 2023-04-01 大陸商江蘇恒瑞醫藥股份有限公司 稠合吡啶環衍生物的可藥用鹽、晶型及其製備方法
WO2023102523A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
CA3237155A1 (en) 2021-12-03 2023-06-08 Zhimin Du Therapeutic compounds for hiv virus infection
US11787825B2 (en) 2021-12-03 2023-10-17 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
TW202400172A (zh) 2022-04-06 2024-01-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
TW202402280A (zh) 2022-07-01 2024-01-16 美商基利科學股份有限公司 可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物
WO2024044477A1 (en) 2022-08-26 2024-02-29 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007238755B2 (en) 2006-04-12 2012-07-12 Merck Sharp & Dohme Llc Pyridyl amide T-type calcium channel antagonists
US20100249176A1 (en) 2007-10-24 2010-09-30 Barrow James C Heterocycle amide t-type calcium channel antagonists
KR20100072266A (ko) * 2007-10-24 2010-06-30 머크 샤프 앤드 돔 코포레이션 헤테로사이클 페닐 아미드 ｔ-형 칼슘 채널 길항제
EP2220046B1 (en) 2007-11-16 2014-06-18 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
EP2401286A4 (en) 2009-02-25 2012-09-26 Bigtec Private Ltd PROBES AND PRIMERS FOR DETECTION OF CHIKUNGUNYA
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US20110035387A1 (en) * 2009-08-10 2011-02-10 Telcordia Technologies, Inc. System and method for the controlled introduction of noise to information filtering
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
WO2011139637A1 (en) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Small-molecule modulators of hiv-1 capsid stability and methods thereof
WO2011143772A1 (en) 2010-05-21 2011-11-24 Boehringer Ingelheim International Gmbh Inhibitors of hiv replication
AP2013006706A0 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc Napht-2-ylacetic acid derivatives to treat AIDS
CN103209963A (zh) 2010-07-02 2013-07-17 吉里德科学公司 作为hiv抗病毒化合物的2-喹啉基-乙酸衍生物
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
SI2688403T1 (sl) 2011-03-23 2017-08-31 Trevena, Inc. Ligandi opioidnih receptorjev in metode uporabe in izdelave istega
ES2707997T3 (es) 2011-04-21 2019-04-08 Gilead Sciences Inc Compuestos de benzotiazol y su uso farmacéutico
JP6205354B2 (ja) 2011-07-06 2017-09-27 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のための化合物
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
EP2736332A4 (en) * 2011-07-29 2015-03-18 Tempero Pharmaceuticals Inc CONNECTIONS AND METHODS
JP5911638B2 (ja) 2012-04-20 2016-04-27 ギリアード サイエンシーズ， インコーポレイテッド ベンゾチアゾール−６−イル酢酸誘導体およびｈｉｖ感染を処置するためのそれらの使用
GB201213087D0 (en) 2012-07-24 2012-09-05 Medical Res Council Inhibition of HIV-1 infection
US9447134B2 (en) 2012-08-17 2016-09-20 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
PT2943493T (pt) 2013-01-09 2017-10-23 Gilead Sciences Inc Compostos terapêuticos para o tratamento de infecções virais
WO2014110298A1 (en) 2013-01-09 2014-07-17 Gilead Sciences, Inc. 5-membered heteroaryls and their use as antiviral agents
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
US20140296266A1 (en) 2013-03-01 2014-10-02 Gilead Sciences, Inc. Therapeutic compounds
GB201312991D0 (en) 2013-07-19 2013-09-04 Isis Innovation Process
US10035760B2 (en) 2013-10-24 2018-07-31 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
PT3186239T (pt) 2014-08-29 2019-01-10 Gilead Sciences Inc Agentes antirretrovirais
US9855230B2 (en) 2014-09-09 2018-01-02 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
CA2983162A1 (en) 2015-04-23 2016-10-27 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
UY36648A (es) 2015-04-23 2016-11-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Inhibidores de la replicación del virus de inmunodeficiencia humana
JP6620763B2 (ja) * 2017-01-16 2019-12-18 マツダ株式会社 電動車両

Also Published As

Publication number Publication date
CN108516974A (zh) 2018-09-11
HUE039521T2 (hu) 2019-01-28
NZ742681A (en) 2019-05-31
EA201591457A1 (ru) 2016-03-31
CN105705500A (zh) 2016-06-22
RS57718B1 (sr) 2018-12-31
CL2015002445A1 (es) 2016-02-19
CA2901502C (en) 2018-07-17
AU2016262671A1 (en) 2016-12-08
CA2901502A1 (en) 2014-09-04
TWI706945B (zh) 2020-10-11
PT2961742T (pt) 2018-10-26
CU20150096A7 (es) 2016-07-29
EP3409667B1 (en) 2021-07-21
NZ631754A (en) 2017-02-24
AU2016262671B2 (en) 2018-11-08
TW201938551A (zh) 2019-10-01
AU2014223973A1 (en) 2015-09-10
CY1121047T1 (el) 2019-12-11
JP2023101723A (ja) 2023-07-21
JP2016510038A (ja) 2016-04-04
PE20151749A1 (es) 2015-12-12
PL2961742T3 (pl) 2018-12-31
CN105705500B (zh) 2018-05-29
EP3409667A1 (en) 2018-12-05
BR112015021027A2 (pt) 2017-07-18
SG10201710764YA (en) 2018-02-27
LT2961742T (lt) 2018-09-25
ZA201506098B (en) 2022-05-25
UY35362A (es) 2014-08-29
AU2014223973B2 (en) 2016-12-22
ES2887578T3 (es) 2021-12-23
HK1226078B (zh) 2017-09-22
TWI694071B (zh) 2020-05-21
HRP20181679T1 (hr) 2018-12-14
KR102229989B1 (ko) 2021-03-18
UA120346C2 (uk) 2019-11-25
DK2961742T3 (en) 2018-09-24
PH12015501881B1 (en) 2016-01-11
JP6519486B2 (ja) 2019-05-29
EP3954679A3 (en) 2022-04-20
EP2961742A2 (en) 2016-01-06
EA035127B1 (ru) 2020-04-30
EP3954679A2 (en) 2022-02-16
US20180273508A1 (en) 2018-09-27
JP2019214599A (ja) 2019-12-19
PE20191461A1 (es) 2019-10-16
ES2688571T3 (es) 2018-11-05
BR112015021027B1 (pt) 2020-02-18
IL240519B (en) 2020-11-30
MD20150092A2 (ro) 2016-02-29
MY195364A (en) 2023-01-16
US20140303164A1 (en) 2014-10-09
US9951043B2 (en) 2018-04-24
EA201591457A8 (ru) 2018-05-31
JP2022009742A (ja) 2022-01-14
MX2015011478A (es) 2016-02-03
SG11201506929VA (en) 2015-10-29
AP2015008717A0 (en) 2015-09-30
AU2018247348A1 (en) 2018-11-08
CA3007006A1 (en) 2014-09-04
SI3409667T1 (sl) 2021-11-30
JP2018141018A (ja) 2018-09-13
CR20190504A (es) 2020-03-11
KR20150121720A (ko) 2015-10-29
PT3409667T (pt) 2021-09-16
EP2961742B1 (en) 2018-08-01
PH12015501881A1 (en) 2016-01-11
US20160108030A1 (en) 2016-04-21
WO2014134566A2 (en) 2014-09-04
US20210009555A1 (en) 2021-01-14
PL3409667T3 (pl) 2021-12-13
TW201446755A (zh) 2014-12-16
NZ728537A (en) 2018-08-31
IL240519A0 (en) 2015-10-29
BR112015021027A8 (pt) 2020-01-14
CR20150454A (es) 2015-11-20
WO2014134566A3 (en) 2014-12-24
JP6893899B2 (ja) 2021-06-23
HK1222169A1 (zh) 2017-06-23
HK1260892A1 (zh) 2019-12-27
SI2961742T1 (sl) 2018-11-30

Similar Documents

Publication Publication Date Title
CU24340B1 (es) Derivados de acetamidas fluoradas para el tratamiento del vih
CO2019001379A2 (es) Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéutico de una infección por el virus del vih .
UY37710A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
UY35263A (es) Compuestos terapéuticos
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
CO2018000660A2 (es) Compuestos derivados del (3β)-cholest-5-en-3-alquil-3-ol y (3β)-cholest-3-alquil-3-ol
CO2017007355A2 (es) Compuestos derivados de pirazincarbozamida y de pirazincarboxilato para el tratamiento de la infección por el virus de hepatitis b
CR20150313A (es) Composiciones farmacéuticas
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
UY36648A (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
UY36212A (es) Moduladores de receptores tipo toll para el tratamiento del vih
CU20170089A7 (es) Derivados de quinazolina utilizados para tratar el vih
NZ732391A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CR20170279A (es) Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
CR20180232A (es) Macrociclos peptídicos contra acinetobacter baumannii
CL2020000487A1 (es) Agentes antivirales contra la hepatitis b.
BR112017020837A2 (pt) compostos de carbamoilpiridona policíclicos e seu uso farmacêutico
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
ECSP11011310A (es) Análogos carba - nucleósido para tratamiento antiviral
CL2017000714A1 (es) Composiciones farmacéuticas de acción prolongada
CU24525B1 (es) Derivado de quinoleína para tratar y prevenir infecciones virales
CU24519B1 (es) Derivados de aminotiazol útiles como agentes antivíricos
CL2014000393A1 (es) Compuestos derivados de benzofurano y sus sales, como inhibidores del virus de hepatitis c; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de una infeccion por el virus de hepatitis c o de una enfermedad asociada con dicha infeccion.
CO2021012579A2 (es) Compuestos útiles en la terapia del vih
DOP2018000035A (es) Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana